Company profile
Ticker
CGON
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
371611499
CGON stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
24 May 24
8-K
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
9 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Other Events
3 May 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Departure of Directors or Certain Officers
16 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
30 Jan 24
S-8
Registration of securities for employees
26 Jan 24
SEC STAFF
SEC staff action: Order
26 Jan 24
424B4
Prospectus supplement with pricing info
25 Jan 24
Latest ownership filings
SC 13G
Unique Diamond Investments Ltd
22 Jul 24
4
Joshua F. Patterson
16 May 24
3
Joshua F. Patterson
16 May 24
SC 13G/A
Decheng Capital Global Life Sciences Fund IV, L.P.
9 Apr 24
4/A
Xiangmin Cui
9 Apr 24
SC 13G
Kissei Pharmaceutical Co., Ltd.
14 Mar 24
SC 13G
TCG Crossover GP I, LLC
9 Feb 24
SC 13G
Decheng Capital Global Life Sciences Fund IV, L.P.
8 Feb 24
SC 13G
Longitude Capital Partners IV, LLC
5 Feb 24
SC 13G
Foresite Capital Fund V, L.P.
5 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 77.47 mm | 77.47 mm | ||||
Cash burn (monthly) | 7.49 mm | 8.67 mm | ||||
Cash used (since last report) | 28.96 mm | 33.53 mm | ||||
Cash remaining | 48.51 mm | 43.94 mm | ||||
Runway (months of cash) | 6.5 | 5.1 |
Institutional ownership, Q1 2024
20.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 11 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.71 bn |
Total shares | 13.86 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Decheng Capital Global Life Sciences Fund IV | 4.96 mm | $183.48 mm |
Kissei Pharmaceutical | 3.54 mm | $131.11 mm |
Longitude Capital Partners IV | 3.19 mm | $118.05 mm |
Foresite Capital Fund V | 2.05 mm | $0.00 |
BK Bank Of New York Mellon | 64.54 k | $2.83 bn |
Sicart Associates | 25.00 k | $1.10 bn |
Capstone Investment Advisors | 18.35 k | $805.74 mm |
BNP Paribas Arbitrage | 11.20 k | $491.59 mm |
AlphaCentric Advisors | 1.00 k | $43.90 mm |
Amalgamated Bank. | 781.00 | $34.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 May 24 | Joshua F. Patterson | Stock Option Common Stock | Grant | Acquire A | No | No | 28.01 | 100,000 | 2.80 mm | 100,000 |
29 Jan 24 | Decheng Capital Global Life Sciences Fund IV | Common Stock | Buy | Acquire P | Yes | No | 19 | 400,000 | 7.60 mm | 400,000 |
29 Jan 24 | Decheng Capital Global Life Sciences Fund IV | Common Stock | Conversion | Acquire C | No | No | 0 | 3,628,198 | 0.00 | 4,558,812 |
29 Jan 24 | Decheng Capital Global Life Sciences Fund IV | Series F Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 4,402,320 | 0.00 | 0 |
29 Jan 24 | Decheng Capital Global Life Sciences Fund IV | Series E Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 21,547,685 | 0.00 | 0 |
29 Jan 24 | Decheng Capital Global Life Sciences Fund IV | Series C Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 8,644,891 | 0.00 | 0 |
29 Jan 24 | Vijay Kasturi | Common Stock | Buy | Acquire P | No | No | 19 | 1,315 | 24.99 k | 1,315 |
29 Jan 24 | Corleen M. Roche | Common Stock | Buy | Acquire P | No | No | 19 | 2,000 | 38.00 k | 2,000 |
News
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
3 Jun 24
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
3 Jun 24
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
28 May 24
Decoding 10 Analyst Evaluations For CG Oncology
14 May 24
Goldman Sachs Upgrades CG Oncology to Buy, Raises Price Target to $50
14 May 24
Press releases
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
6 Jun 24
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
24 May 24
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
3 May 24